Clinical and Correlative Pilot Study Of Carfilzomib, Lenalidomide, and Dexamethasone Followed By Lenalidomide Extended Dosing (CRd - R) In High Risk Smoldering Multiple Myeloma Patients

被引：3
|
作者：
Landgren, Ola
Mailankody, Sham
Kwok, Mary
Manasanch, Elisabet E.
Bhutani, Manisha
Tageja, Nishant
Kazandjian, Dickran
Zingone, Adriana
Costello, Rene
Burton, Debra
Zhang, Yong
Wu, Peter
Carter, George
Mulquin, Marcia
Zuchlinski, Diamond
Maric, Irina
Calvo, Katherine R.
Braylan, Raul C.
Yuan, Constance
Stetler-Stevenson, Maryalice
Arthur, Diane C.
Lindenberg, Liza
Kurdziel, Karen
Choyke, Peter
Steinberg, Seth M.
Roschewski, Mark
Korde, Neha
机构：
来源：
BLOOD | 2013年 / 122卷 / 21期
关键词：
D O I：
10.1182/blood.V122.21.1939.1939
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1939
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Phase II Trial of the Combination of Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma
    Bustoros, Mark
    Liu, Chia-jen
    Reyes, Kaitlen
    Hornburg, Kalvis
    Guimond, Kathleen
    Styles, Rachel
    Savell, Alexandra
    Berrios, Brianna
    Warren, Diane
    Dumke, Henry
    Rivotto, Bradley
    Henrick, Patrick
    Scranton, Emily
    Leblebjian, Houry
    Meid, Kirsten
    Schlossman, Robert L.
    Munshi, Nikhil
    Laubach, Jacob
    Anderson, Kenneth C.
    Richardson, Paul
    Ghobrial, Irene M.
    BLOOD, 2018, 132
  • [32] Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma
    Liu, Chia-Jen
    Ghobrial, Irene M.
    Bustoros, Mark
    Reyes, Kaitlen
    Hornburg, Kalvis
    Badros, Ashraf Z.
    Vredenburgh, James J.
    Boruchov, Adam
    Matous, Jeffrey V.
    Caola, Aaron
    Rivotto, Bradley
    Savell, Alexandra
    Henrick, Patrick
    Paba-Prada, Claudia E.
    Schlossman, Robert L.
    Laubach, Jacob
    Rosenblatt, Jacalyn
    Yee, Andrew J.
    Nadeem, Omar
    Maegawa, Rodrigo O.
    Jakubowiak, Andrzej
    Usmani, Saad Z.
    Bhutani, Manisha
    Cappuccio, Joseph
    Berrios, Brianna
    Noonan, Kimberly
    Zavidij, Oksana
    Mouhieddine, Tarek H.
    Boehner, Cody J.
    Neuse, Carl-Jannes
    Salem, Karma Ziad
    Reidy, Mairead
    Park, Jihye
    Agius, Michael
    Rahmat, Mahshid
    Manier, Salomon
    Bhutani, Divaya
    Zonder, Jeffrey A.
    Munshi, Nikhil
    Auclair, Daniel
    Anderson, Kenneth
    Richardson, Paul
    BLOOD, 2018, 132
  • [33] A Phase II Trial of the Combination of Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma
    Nadeem, Omar
    Reed, Robert A.
    Prescott, Julia
    Tague, Kelsey
    Romines, Veronica
    Metivier, Amada
    Savell, Alexandra
    Leblebjian, Houry
    Distaso, Alexandra
    Mo, Clifton C.
    Laubach, Jacob P.
    Sperling, Adam S.
    Richardson, Paul G.
    Ghobrial, Irene M.
    BLOOD, 2021, 138
  • [34] Phase II Trial of the Combination of Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma
    Bustoros, Mark
    Nadeem, Omar
    Sperling, Adam S.
    Bianchi, Giada
    Ardente, Lily
    Redd, Robert A.
    Prescott, Julia
    Frey, Erin
    Guimond, Kathleen
    Styles, Rachel
    Hornburg, Kalvis
    Savell, Alexandra
    Su, Nang Kham
    Bindra, Govind
    Boehner, Cody J.
    Reyes, Kaitlen
    Leblebjian, Houry
    Warren, Diane
    Munshi, Nikhil C.
    Laubach, Jacob P.
    Anderson, Kenneth C.
    Richardson, Paul G.
    Ghobrial, Irene M.
    BLOOD, 2019, 134
  • [35] PHASE II TRIAL OF COMBINATION OF ELOTUZUMAB, LENALIDOMIDE, AND DEXAMETHASONE IN HIGH-RISK SMOLDERING MULTIPLE MYELOMA
    Ghobrial, I.
    Caola, A.
    Henrick, P.
    Savell, A.
    Cappuccio, J.
    Rivotto, B.
    Reyes, K.
    Paba-Prada, C.
    Schlossman, R.
    Laubach, J.
    Richardson, P.
    Noonan, K.
    Munshi, N.
    Liu, C-J.
    Bustoros, M.
    Badros, A.
    Matous, J.
    Rosenblatt, J.
    Yee, A.
    Maegawa, R.
    Usmani, S.
    Vredenburgh, J.
    Boruchov, A.
    Nadeem, O.
    Bhutani, D.
    Jakubowiak, A.
    Bhutani, M.
    Salem, K.
    Manier, S.
    Park, J.
    HAEMATOLOGICA, 2017, 102 : 317 - 317
  • [36] Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Therapy in High-Risk Newly Diagnosed Multiple Myeloma
    Tan, Carlyn
    Korde, Neha
    Derkach, Andriy
    Hultcrantz, Malin
    Maclachlan, Kylee H.
    Hassoun, Hani
    Mailankody, Sham
    Shah, Urvi A.
    Rajeeve, Sridevi
    Patel, Dhwani
    Lesokhin, Alexander
    Lahoud, Oscar Boutros
    Shah, Gunjan L.
    Scordo, Michael
    Chung, David
    Landau, Heather
    Giralt, Sergio A.
    Hofmeister, Craig C.
    Kaufman, Jonathan L.
    Nooka, Ajay K.
    Usmani, Saad Z.
    Lonial, Sagar
    Joseph, Nisha S.
    BLOOD, 2023, 142
  • [37] Phase II trial of daratumumab, bortezomib, lenalidomide and dexamethasone in high-risk smoldering multiple myeloma
    Nadeem, Omar
    Redd, Robert
    Mo, Clifton
    Laubach, Jacob
    Richardson, Paul G.
    Prescott, Julia
    Marto, Marjorie
    Davie, Christine
    Ricciardi, Caroline
    Murphy, Elizabeth
    Bertoni, Meredith
    Choden, Dechen
    Magidson, Sophie
    Sheehan, Brian
    Shrestha, Hira
    Sperling, Adam S.
    O'Donnell, Elizabeth K.
    Ghobrial, Irene M.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S89 - S89
  • [38] Longitudinal 18f-FDG-PET-CT Analysis in Newly Diagnosed Multiple Myeloma (NDMM) Patients Following Carfilzomib, Lenalidomide, Dexamethasone Induction and Lenalidomide Maintenance (CRd-R)
    Korde, Neha S.
    Kazandjian, Dickran
    Roschewski, Mark
    Mailankody, Sham
    Hultcrantz, Malin
    Yuan, Constance M.
    Stetler-Stevenson, Maryalice
    Choyke, Peter
    Hassoun, Hani
    Lesokhin, Alexander M.
    Lendvai, Nikoletta
    Smith, Eric L.
    Landgren, Ola
    Kurdziel, Karen A.
    Lindenberg, Maria Liza
    BLOOD, 2016, 128 (22)
  • [39] Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
    Siegel, David S.
    Dimopoulos, Meletios A.
    Ludwig, Heinz
    Facon, Thierry
    Goldschmidt, Hartmut
    Jakubowiak, Andrzej
    San-Miguel, Jesus
    Obreja, Mihaela
    Blaedel, Julie
    Stewart, A. Keith
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (08) : 728 - +
  • [40] The Role of 18f-FDG-PET/CT in Characterizing Depth of Response in High Risk Smoldering Multiple Myeloma Patients Treated with Carfilzomib, Lenalidomide, and Dexamethasone (KRd)
    Hill, Elizabeth
    Korde, Neha
    Morrison, Candis
    Dew, Alexander
    Carpenter, Ashley
    Epstein, Monica
    Lu, Crystal
    Choyke, Peter
    Mena, Esther
    Lindenberg, Liza
    Landgren, Ola
    Kazandjian, Dickran
    BLOOD, 2020, 136
12345